NEW YORK (GenomeWeb) – Quidel today announced that the US Food and Drug Administration has cleared the company's AmpliVue Trichomonas Assay for marketing. 

The assay detects nucleic acids isolated from vaginal swab specimens obtained by clinicians from symptomatic and asymptomatic female patients. It runs on Quidel's AmpliVue handheld molecular diagnostic device and does not require upfront DNA extraction. Quidel said the assay generates results in about 50 minutes. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.